Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Longitudinal Research02:20

Longitudinal Research

13.7K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.7K
Longitudinal Studies01:26

Longitudinal Studies

670
Longitudinal studies are also widely used in other medical and social science fields. For instance, in cardiovascular research, they can monitor patients' health over decades to identify risk factors for heart disease, such as high cholesterol or smoking, and evaluate the long-term effectiveness of preventive measures. Similarly, in mental health studies, researchers might follow individuals from adolescence into adulthood to understand the development and progression of conditions like...
670
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of survival in genetic frontotemporal dementia.

The Lancet. Neurology·2026
Same author

A convergence of global epidemics: diabetes as a modulator of neurodegenerative and neuro-inflammatory disorders.

Frontiers in neurology·2026
Same author

Compositional recombination is facilitated by a distributed cortico-cerebellar network.

Cell reports·2026
Same author

TASIT super short: Empirical development of a social cognition screener.

The Clinical neuropsychologist·2026
Same author

Feasibility of Internet-Based Mind-Body Training for Adults With Subjective Cognitive Decline: Protocol for a Randomized Controlled Trial.

JMIR research protocols·2026
Same author

Abnormalities in core AD biomarkers precede inflammatory and glial markers in CSF in Autosomal Dominant Alzheimer's Disease.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Mar 31, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.5K

Progression in Behavioral Variant Frontotemporal Dementia: A Longitudinal Study.

Emma Devenney1, Lauren Bartley2, Chris Hoon2

  • 1Neuroscience Research Australia, Sydney, Australia2Prince of Wales Clinical School, University of New South Wales, Sydney, Australia3Brain and Mind Research Institute, Sydney, Australia.

JAMA Neurology
|October 27, 2015
PubMed
Summary

Behavioral variant frontotemporal dementia (BVFTD) progresses variably. Detailed assessments can identify prognostic features in possible BVFTD, aiding clinical diagnosis and management.

More Related Videos

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia
13:08

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia

Published on: December 2, 2015

9.5K
Assessment of Social Transmission of Food Preferences Behaviors
04:56

Assessment of Social Transmission of Food Preferences Behaviors

Published on: January 25, 2018

8.6K

Related Experiment Videos

Last Updated: Mar 31, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.5K
Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia
13:08

Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia

Published on: December 2, 2015

9.5K
Assessment of Social Transmission of Food Preferences Behaviors
04:56

Assessment of Social Transmission of Food Preferences Behaviors

Published on: January 25, 2018

8.6K

Area of Science:

  • Neuroscience
  • Neurology
  • Clinical Medicine

Background:

  • A significant gap exists in understanding the progression of behavioral variant frontotemporal dementia (BVFTD).
  • There is a clinical need for better markers to differentiate FTD from phenocopies and to predict disease progression.
  • Accurate prognostication is crucial for managing patients with possible BVFTD.

Purpose of the Study:

  • To longitudinally track outcomes and progression in probable and possible BVFTD cases.
  • To identify clinical features that can improve prognostication for possible BVFTD.
  • To enhance diagnostic accuracy and clinical management strategies for FTD.

Main Methods:

  • A longitudinal cohort study was conducted in a specialist FTD research clinic.
  • Fifty-eight patients with possible, probable, or definite BVFTD were followed from 2008 to 2013.
  • Clinical, genetic, neuropsychological, and neuroimaging data were analyzed to assess progression and prognostic factors.

Main Results:

  • Of 58 patients, 38 initially met criteria for probable BVFTD, with most maintaining or converting to definite diagnosis.
  • Twenty patients initially met possible BVFTD criteria; 11 (55%) progressed to probable/definite BVFTD, with 8 carrying the C9orf72 expansion.
  • Positive family history, memory impairment, and early clinical abnormalities were significant predictors of progression (P < .05).

Conclusions:

  • Behavioral variant FTD exhibits diverse progression patterns over time.
  • Comprehensive neurological and cognitive assessments can reveal key prognostic indicators in possible BVFTD.
  • A probable BVFTD diagnosis demonstrates high accuracy in clinical settings, guiding patient care.